Andrew Tsai
Stock Analyst at Jefferies
(3.23)
# 1,101
Out of 5,115 analysts
28
Total ratings
54.55%
Success rate
3.2%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $16.88 | +77.73% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.56 | +61.23% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $44.07 | -31.93% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $314.00 | +43.31% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $17.69 | +80.89% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $15.48 | +61.50% | 2 | Nov 12, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | $22 → $20 | $21.57 | -7.28% | 1 | Oct 22, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $179.89 | +5.62% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $20.34 | +72.07% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $30.37 | -1.22% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $77.27 | -9.41% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.48 | -28.16% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $184.25 | +8.55% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $18.72 | +44.23% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $3.55 | +266.20% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.61 | +31.53% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.16 | +158.62% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.76 | +618.09% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $41.01 | -43.92% | 1 | Jun 1, 2020 |
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $16.88
Upside: +77.73%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.56
Upside: +61.23%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $44.07
Upside: -31.93%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $314.00
Upside: +43.31%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $17.69
Upside: +80.89%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $15.48
Upside: +61.50%
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: $22 → $20
Current: $21.57
Upside: -7.28%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $179.89
Upside: +5.62%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $20.34
Upside: +72.07%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $30.37
Upside: -1.22%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $77.27
Upside: -9.41%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.48
Upside: -28.16%
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $184.25
Upside: +8.55%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.72
Upside: +44.23%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $3.55
Upside: +266.20%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $26.61
Upside: +31.53%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.16
Upside: +158.62%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.76
Upside: +618.09%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $41.01
Upside: -43.92%